Oryzon Genomics SA (ES:ORY)
BME:ORY
Want to see ES:ORY full AI Analyst Report?
Top Page
Oryzon Genomics SA
(BME:ORY)
Select Model
Select Model
Rating:46Neutral
Price Target:
€3.00
▼(-6.83% Downside)
Action:Reiterated
Date:03/06/26
The score is held back primarily by ongoing losses, inconsistent revenue, and persistent cash burn despite a comparatively supportive balance sheet with low leverage. Technically, the stock is in a downtrend (below key moving averages) with weak momentum, though indicators appear oversold. Valuation is difficult to assess with a negative P/E and no dividend data.
Positive Factors
Balance Sheet Strength
A stronger equity base and low debt provide durable financial flexibility for a clinical-stage biotech. That position reduces short-term insolvency risk, supports continued R&D spending or partnering negotiations, and lessens immediate reliance on hostile or dilutive financing.
Negative Factors
Persistent Cash Burn
Chronic negative operating and free cash flow creates an ongoing need for external funding to sustain development. Over months this forces reliance on equity raises or deals, increasing dilution risk and potentially constraining strategic choices or timelines if financing terms tighten.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
A stronger equity base and low debt provide durable financial flexibility for a clinical-stage biotech. That position reduces short-term insolvency risk, supports continued R&D spending or partnering negotiations, and lessens immediate reliance on hostile or dilutive financing.
Read all positive factors
Oryzon Genomics SA (ORY) vs. iShares MSCI Spain ETF (EWP)
Market Cap
€238.92M
Dividend YieldN/A
Average Volume (3M)1.68M
Price to Earnings (P/E)―
Beta (1Y)0.64
Revenue GrowthN/A
EPS Growth58.10%
CountryES
Employees47
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.06
Shares Outstanding79,887,700
10 Day Avg. Volume2,474,153
30 Day Avg. Volume1,678,358
Financial Highlights & Ratios
PEG Ratio2.31
Price to Book (P/B)2.19
Price to Sales (P/S)0.00
P/FCF Ratio-95.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.40Price Target Upside98.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.12
Revenue Forecast (FY)€8.20M
Oryzon Genomics SA Business Overview & Revenue Model
Company Description
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a...
How the Company Makes Money
Oryzon Genomics primarily aims to generate revenue through the development and commercialization of its drug candidates and through partnering activities typical of clinical-stage biotech companies. Potential revenue streams include: (1) collabora...
Oryzon Genomics SA Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
68
Positive
Cash Flow
27
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.58M | 0.00 | 7.36M | 14.19M | 0.00 | 10.62M |
| Gross Profit | 11.06M | -133.91K | 7.06M | 13.95M | 15.23M | 9.87M |
| EBITDA | -1.69M | -6.29M | -4.43M | -4.43M | -5.35M | -6.88M |
| Net Income | -4.04M | -2.61M | -3.67M | -3.35M | -4.23M | -4.69M |
Balance Sheet | ||||||
| Total Assets | 138.35M | 144.52M | 108.72M | 106.90M | 103.70M | 95.38M |
| Cash, Cash Equivalents and Short-Term Investments | 31.11M | 28.37M | 5.62M | 12.26M | 21.32M | 28.72M |
| Total Debt | 13.73M | 11.94M | 16.21M | 13.69M | 17.44M | 17.66M |
| Total Liabilities | 24.13M | 26.68M | 21.67M | 25.13M | 31.13M | 24.12M |
| Stockholders Equity | 114.22M | 105.45M | 87.04M | 81.77M | 72.57M | 71.26M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -2.42M | -13.40M | -15.08M | -16.12M | -15.39M |
| Operating Cash Flow | 0.00 | -2.36M | -5.69M | -574.96K | -1.85M | -3.63M |
| Investing Cash Flow | 0.00 | -11.04M | -7.81M | -14.50M | -14.27M | -11.72M |
| Financing Cash Flow | 0.00 | 36.13M | 6.87M | 6.02M | 8.71M | 4.12M |
Oryzon Genomics SA Technical Analysis
Neutral
3.22
Price Trends
2.86
Positive
2.96
Positive
3.05
Negative
Market Momentum
0.07
Negative
57.70
Neutral
30.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:ORY, the sentiment is Neutral. The current price of 3.22 is above the 20-day moving average (MA) of 2.96, above the 50-day MA of 2.86, and above the 200-day MA of 3.05, indicating a neutral trend. The MACD of 0.07 indicates Negative momentum. The RSI at 57.70 is Neutral, neither overbought nor oversold. The STOCH value of 30.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ES:ORY.
Oryzon Genomics SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | €1.68B | 20.16 | 35.74% | 1.04% | 28.27% | 307.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | €1.41B | 10.71 | 18.13% | 3.51% | 23.66% | -28.51% | |
46 Neutral | €238.92M | -108.79 | -2.58% | ― | ― | 58.10% | |
46 Neutral | €220.51M | 50.05 | 2.03% | 1.91% | -3.23% | -60.06% |
* Healthcare Sector Average
ES:ORY
Oryzon Genomics SA
3.03
0.13
4.55%
ES:FAE
Faes Farma
4.57
0.43
10.32%
ES:RJF
LABORATORIO REIG JOFRE
2.70
-0.49
-15.44%
ES:PHM
Pharma Mar SA
94.25
3.25
3.58%
ES:IKM
1nKemia IUCT Group SA
0.31
0.00
0.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.